CN114468196A - Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof - Google Patents
Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof Download PDFInfo
- Publication number
- CN114468196A CN114468196A CN202210199609.0A CN202210199609A CN114468196A CN 114468196 A CN114468196 A CN 114468196A CN 202210199609 A CN202210199609 A CN 202210199609A CN 114468196 A CN114468196 A CN 114468196A
- Authority
- CN
- China
- Prior art keywords
- coenzyme
- parts
- effervescent tablet
- vitamin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 39
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 38
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229940110767 coenzyme Q10 Drugs 0.000 title claims abstract description 32
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003513 alkali Substances 0.000 claims abstract description 30
- 239000002253 acid Substances 0.000 claims abstract description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 239000000314 lubricant Substances 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 12
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 12
- 239000001508 potassium citrate Substances 0.000 claims abstract description 12
- 229960002635 potassium citrate Drugs 0.000 claims abstract description 12
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims abstract description 12
- 235000011082 potassium citrates Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000003765 sweetening agent Substances 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 12
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 12
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 12
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 11
- 239000000945 filler Substances 0.000 claims abstract description 11
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 7
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 7
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 6
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 6
- 239000011720 vitamin B Substances 0.000 claims abstract description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 24
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 24
- 229940013618 stevioside Drugs 0.000 claims description 24
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 24
- 235000019202 steviosides Nutrition 0.000 claims description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 19
- 239000008101 lactose Substances 0.000 claims description 19
- 239000011975 tartaric acid Substances 0.000 claims description 19
- 235000002906 tartaric acid Nutrition 0.000 claims description 19
- 239000008118 PEG 6000 Substances 0.000 claims description 17
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 17
- 238000007873 sieving Methods 0.000 claims description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 229920003081 Povidone K 30 Polymers 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003792 electrolyte Substances 0.000 abstract description 5
- 210000004165 myocardium Anatomy 0.000 abstract description 5
- 229940088594 vitamin Drugs 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 5
- 235000013343 vitamin Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000000686 essence Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 239000007884 disintegrant Substances 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 8
- 230000009194 climbing Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000017946 PGC-1 Human genes 0.000 description 7
- 108700038399 PGC-1 Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 210000003194 forelimb Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 108700000707 bcl-2-Associated X Proteins 0.000 description 5
- 102000055102 bcl-2-Associated X Human genes 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 235000005976 Citrus sinensis Nutrition 0.000 description 4
- 240000002319 Citrus sinensis Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 101150087698 alpha gene Proteins 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- -1 p-AMPKP Proteins 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a compound multivitamin coenzyme Q10 effervescent tablet and a preparation method thereof, wherein the effervescent tablet comprises the following components: raw materials, an acid source and an alkali source, a sweetening agent, a lubricating agent, a filling agent, a binding agent, essence and polysorbate-80; the raw materials comprise, by weight, 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate. The invention firstly proposes to develop a compound preparation which is rich in coenzyme Q10, multiple vitamins, electrolytes, energy and other nutrient substances needed by organisms, and the novel preparation has the advantages of good administration compliance, convenient carrying, rapid absorption, high bioavailability, good taste and the like. The product has effects in improving energy supply, inhibiting active oxygen generation, nourishing myocardium, and relieving exercise fatigue.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a compound multivitamin coenzyme Q10 effervescent tablet and a preparation method thereof.
Background
No matter whether athletes or ordinary body builders, when doing high-intensity exercises or training, the problems of physical energy consumption, body fatigue, heart load aggravation and the like are faced, and simultaneously, the loss and the loss of vitamins, electrolytes, energy and the like of the body are caused. Therefore, there is an urgent need for a sports health and anti-fatigue preparation which can rapidly relieve fatigue, nourish cardiac muscle, specifically supplement essential nutrients lost by the body, solve the problem of energy and nutrition supplementation after a large amount of physical energy consumption or physical energy exhaustion during sports or training, reduce the occurrence of cardiac risk events, and relieve motility.
Disclosure of Invention
The purpose of the invention is as follows: the invention provides a compound multi-dimensional coenzyme Q10 effervescent tablet and a preparation method thereof, and aims to solve the problems of energy and nutrition supplement after a large amount of physical energy is consumed or the physical energy is exhausted in the process of officer and soldier high-intensity combat and training of troops.
The technical scheme is as follows:
a compound multivitamin coenzyme Q10 effervescent tablet comprises the following components in percentage by mass:
the raw materials comprise, by weight, 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate.
Preferably, the filler is lactose; the adhesive is PVP K30; the sweetener is stevioside; the lubricant is PEG 6000.
Preferably, the alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1-1.2: 1.
A preparation method of compound multivitamin coenzyme Q10 effervescent tablets comprises the steps of mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source, half of a filling agent, a bonding agent and a sweetening agent in percentage by mass according to parts by weight, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 in percentage by mass, grinding uniformly, adding an alkali source and half of filler, adhesive and sweetener in percentage by mass, sieving with a 20-mesh sieve, granulating, and drying to obtain alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.
Has the advantages that: the invention firstly proposes to develop a compound preparation rich in coenzyme Q10, multiple vitamins, electrolytes, energy and other nutrients required by organisms, and the novel preparation has the advantages of good administration compliance, convenient carrying, rapid absorption, high bioavailability, good taste and the like. The product has effects in improving energy supply, inhibiting active oxygen generation, nourishing myocardium, and relieving exercise fatigue.
Drawings
Figure 1 is the effect of the acid-base ratio of the effervescent disintegrant on pH;
FIG. 2 is an A-B response surface plot and a contour plot;
FIG. 3 is an A-C response surface plot and a contour plot;
FIG. 4 is a B-C response surface plot and a contour plot;
FIG. 5 shows experimental results of experimental behavioural tests of weight swimming of mice;
FIG. 6 shows experimental behavioural test results of the grip strength of the forelimb of a mouse;
FIG. 7 shows the experimental results of mouse rod rotation;
FIG. 8 shows the experimental results of the mouse climbing rod experiment;
FIG. 9 is the level of MDA in mouse serum;
FIG. 10 is the level of SOD in mouse serum;
FIG. 11 is the level of LD in mouse serum;
FIG. 12 is the level of BUN in mouse serum;
FIG. 13 is the level of mouse liver glycogen;
FIG. 14 is HE staining;
FIG. 15 is reverse transcription-real-time fluorescence quantitative PCR;
FIG. 16 Effect of AMPK, p-AMPKP, GC-1. alpha. protein expression in gastrocnemius muscle after mouse exercise;
FIG. 17 Effect of Bcl-2, Bax protein expression in gastrocnemius muscle after exercise in mice.
Detailed Description
The invention is described in more detail below with reference to the accompanying drawings.
The invention firstly proposes that the coenzyme Q10 and vitamins and the like are combined together, so that the energy is supplemented, the cardiac muscle can be nourished, and the fatigue is relieved. In the preparation process, polysorbate 80 and coenzyme Q10 are added and ground uniformly to play a role in solubilization.
Example 1
The compound multivitamin coenzyme Q10 effervescent tablet comprises 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate, wherein the mass percentages of the raw materials and other components are as follows: 3% of raw materials, 70% of acid source and alkali source, 2% of stevioside, 2% of PEG 60003%, 17% of lactose, 302% of PVP K, 2% of essence and 801% of polysorbate.
The alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1.2: 1.
A preparation method of compound multivitamin coenzyme Q10 effervescent tablets comprises the steps of mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source, half of lactose, PVP K30 and stevioside in percentage by weight, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 according to weight parts and mass percentage, grinding uniformly, adding an alkali source, half of lactose, PVP K30 and stevioside according to mass percentage, sieving with a 20-mesh sieve, granulating, drying, and preparing into alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.
Example 2
The compound multivitamin coenzyme Q10 effervescent tablet comprises 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate, wherein the mass percentages of the raw materials and other components are as follows: 5% of raw materials, 60% of acid source and alkali source, 3% of stevioside, PEG 60004%, 22.5% of lactose, 302% of PVP K, 2% of essence and 801.5% of polysorbate.
The alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1.1: 1.
A preparation method of compound multivitamin coenzyme Q10 effervescent tablets comprises the steps of mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source, half of lactose, PVP K30 and stevioside in percentage by weight, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 according to weight parts and mass percentage, grinding uniformly, adding an alkali source, half of lactose, PVP K30 and stevioside according to mass percentage, sieving with a 20-mesh sieve, granulating, drying, and preparing into alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.
Example 3
The compound multivitamin coenzyme Q10 effervescent tablet comprises 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate, wherein the mass percentages of the raw materials and other components are as follows: 1% of raw materials, 75% of acid source and alkali source, 1% of stevioside, PEG 60002%, 18.5% of lactose, 301% of PVP K, 1% of essence and-800.5% of polysorbate.
The alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1: 1.
A preparation method of compound multivitamin coenzyme Q10 effervescent tablets comprises the steps of mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source, half of lactose, PVP K30 and stevioside in percentage by weight, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 according to weight parts and mass percentage, grinding uniformly, adding an alkali source, half of lactose, PVP K30 and stevioside according to mass percentage, sieving with a 20-mesh sieve, granulating, drying, and preparing into alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.
In the raw materials of the invention, the raw materials,
coenzyme Q10: scavenging free radicals, resisting oxidation, protecting heart, relieving fatigue, and enhancing immunity.
Vitamin C: promoting collagen synthesis, resisting oxidation, and improving immunity.
Nicotinamide: is a component of coenzyme I and coenzyme II, becomes a coenzyme of a plurality of dehydrogenases, participates in biological oxidation, and has the function of whitening skin.
Vitamin B6: the blood glucose concentration is kept stable during exercise, smooth glucose catabolism is guaranteed, exercise hypoglycemia is prevented, concentration of pyruvic acid in muscle cells is prevented from rising, lactic acid is reduced, and fatigue caused by exercise is delayed.
Potassium citrate: maintaining normal excitability of cardiac and neuromuscular.
Zinc gluconate: promote the synthesis of nucleic acid, protein and carbohydrate.
The main medicines supplement each other, can specifically supplement essential nutrient components lost by the body, solve the problems of energy and nutrition supplement after a large amount of physical energy consumption or physical energy exhaustion in the process of sports or training, and relieve exercise-induced fatigue.
The determination of the filler and the adhesive the filler is of various types, such as lactose, sucrose, aspartame, mannitol and the like, and mainly plays a role in protecting materials and increasing the volume. The adhesive plays a role in shaping in the granulating process, can strengthen the combination among particles, and is commonly starch slurry, PVP K30, Arabic gum slurry, microcrystalline cellulose and the like. The filler can be starch, dextrin, lactose, sucrose, mannitol and the like, the starch and the dextrin have poor water solubility, the sucrose is easy to absorb moisture, the mannitol has high cost, the lactose has no hygroscopicity, the solution is clear, and the compressibility is good, so the preferable filler is the lactose; the adhesive is PVP K30, an absolute ethyl alcohol solution of 5% PVP K30 is adopted, agglomeration is not prone to occurring in the granulating process, and drying is rapid; the sweetener is stevioside; the lubricant is PEG 6000; the essence can be any existing flavor essence, such as sweet orange essence and the like.
The acid-base ratio of the effervescent disintegrant is determined, sodium bicarbonate is usually selected as an alkali source of the effervescent disintegrant, citric acid and tartaric acid are more common acid sources, the citric acid is extremely easy to absorb moisture, the humidity needs to be strictly controlled, the citric acid is easy to be adhered and washed, the tartaric acid is relatively stable, and the requirement on the environment is not high, so that the tartaric acid and the sodium bicarbonate are respectively selected as the acid source and the alkali source. The adding amount of the effervescent disintegrant is 70%, the stevioside is 2.0%, the PEG6000 is 4%, the sweet orange essence is 1%, the balance is lactose, the mass ratios of tartaric acid and sodium bicarbonate are respectively 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1 and 1.3:1, and the acid-base ratio of the effervescent disintegrant is screened by taking the PH, the disintegration time limit and the mouth feel as indexes. When the proportion of sodium bicarbonate is high, the taste is astringent, the proportion of tartaric acid is too large, the pH is low, the taste is sour, and the tablet is easy to be sticky and flushed. As can be seen from Table 1 and FIG. 1, when the mass ratio of tartaric acid to sodium bicarbonate is 1.2:1, the effervescent tablet has good taste, rapid disintegration, and no sticky punch phenomenon.
TABLE 1 test results for acid-base ratio of effervescent disintegrant
Determining the dosage of the effervescent disintegrant, namely, fixing the mass ratio of tartaric acid to alkali to be 1:1, the mass ratio of stevioside to alkali to be 2.0%, PEG6000 to be 4%, the mass ratio of orange essence to be 1% and the mass ratio of the rest to be lactose, and respectively performing tests on the dosages of the effervescent disintegrant to be 50%, 60%, 70%, 80% and 90% to determine the dosage of the effervescent disintegrant. The influence of the dosage of the effervescent disintegrant on the pH is small, and as can be seen from Table 2, when the dosage is 60-80%, the disintegration time of the effervescent tablet is short, so that response surface tests are carried out by selecting the dosages of the effervescent disintegrant to be 60%, 70% and 80%.
Table 2 test results for effervescent disintegrant dosage
The use amount of the sweetening agent is determined, the stevioside is a natural sweetening agent, the sweetness is 200-300 times that of cane sugar, the calorie is far lower than that of cane sugar, and the safety is high, so that the stevioside is selected as the sweetening agent in the experiment and is used for improving the taste of the effervescent tablet. The mass ratio of tartaric acid to alkali is fixed to be 1:1, the dosage of the effervescent disintegrant is 70%, the PEG6000 is 4%, the sweet orange essence is 1%, the balance is lactose, the adding amount of stevioside is respectively 1%, 1.5%, 2%, 2.5% and 3%, and the dosage of the stevioside is determined.
As the addition amount of stevioside was gradually increased, the sweetness of the effervescent tablet was gradually increased, and when the addition amount was 1%, the sweetness was weak, and when the addition amount was 3%, the sweetness was too strong, as can be seen from table 3, when the addition amount was 1.5% to 2.5%, the mouth feel was relatively good, so that the response surface test was performed by selecting the addition amounts of stevioside of 1.5%, 2%, and 2.5%.
TABLE 3 sweetening agent dosage test results
The determination of the dosage of the lubricant can improve the fluidity, so that the surface of the tablet is smooth and flat, otherwise, the problems of sticking, cracking, difficult tabletting and the like can occur. The commonly used lubricant is magnesium stearate, aerosil, PEG6000, etc. PEG6000 has good lubricating property, and after the PEG6000 is dissolved in water, the solution is clear and has no precipitate, so the PEG6000 is selected as the lubricant in the test. The mass ratio of tartaric acid to alkali is fixed to be 1:1, the dosage of the effervescent disintegrant is 70%, the dosage of stevioside is 2.0%, the dosage of the sweet orange essence is 1%, the rest is lactose, the addition amounts of PEG6000 are respectively 1%, 2%, 3%, 4% and 5%, and the dosage of PEG6000 is determined.
When the dosage of PEG6000 is 1%, the surface of the effervescent tablet is not smooth enough and the effervescent tablet is easy to loosen, while when the dosage is 5%, the effervescent tablet is slow to disintegrate and the viscosity is increased, and when the dosage of PEG6000 is 2% -4%, the effervescent tablet is smooth in surface and fast to disintegrate. As can be seen from Table 4, the response surface test was carried out with the amounts of PEG6000 selected at 2%, 3% and 4%.
TABLE 4 Lubricant usage test results
Selecting Box-Behnken to establish a model, taking the dosage of the effervescent disintegrant (A), the dosage of stevioside (B) and the dosage of PEG6000 (C) as evaluation factors, taking sensory score as an evaluation index, and adopting Design-Expert software to perform data processing and analysis. The results are shown in tables 5 and 6.
By regression fitting, a regression equation is established as: y ═ 9.46+0.1875A-0.0750B-0.0375C-0.0750AB-0.0500 AC +0.1750BC-1.16A2-0.7300B2-0.5550C2. F-57.02, P of regression model<0.0001, the model is significant. The mismatching term F is 2.37, and P is 0.2114>0.05, which shows that the regression equation fits well. The first term a, the second terms BC and A, B, C have a significant effect on the response values. By comparison of the F values, the three factors influence sensory scores in the order: a. the>B>C。
The steeper the curve, the greater the effect of this factor on the response value, as shown in the response surface plots (fig. 2-4). The curved surfaces of A, B, A and C are steeper, indicating that the use level of the effervescent disintegrant and the stevioside has more obvious influence on the sensory score; the curved surfaces of C and B are relatively flat, which shows that the influence of the dosage of PEG6000 on the sensory score is small.
The parameters are optimized and analyzed to obtain the optimal conditions of 70.8 percent of disintegrant dosage, 2 percent of stevioside and 2 percent of PEG 60003 percent, samples are prepared according to the conditions, process verification is carried out, the measured sensory score is 9.4 and is similar to the predicted value of 9.47, and the conditions are stable and reliable.
TABLE 5 Box-Behnken test results
TABLE 6 results of analysis of variance of response surface model
Note: p <0.05, indicating that the model or the investigation factor has a significant influence; p <0.0001, indicates a very significant effect experiment 1 behavioral test
1.1 Experimental animals
60 KM mice of 4-5 weeks are selected, the mice are clean, and the mice have the weight of 20 +/-2 g and are divided into 5 groups, wherein each group comprises 12 mice, and each half of the mice is a blank group (control), a Low dose group (Low), a Medium dose group (Medium), a High dose group (High) and a Positive drug group (Positive). Supplied by Liaoning Biometrics, Inc. (license number: SCXK (Liao) 2020 + 0001). The breeding temperature is 21-24 ℃, the humidity is 40% -60%, drinking water is freely taken, the environment is adapted, and experiments are carried out after one week.
1.2 mouse weight bearing swimming experiment
The gavage compound multidimensional coenzyme Q10 effervescent tablet is continuously administrated for 30d, the last administration is carried out for 60min, a lead skin load with the mass being 5% of the body mass of a mouse is tied at the tail of the mouse, the mouse is placed in a swimming box with the water depth being 30cm and the water temperature being 30 +/-0.5℃ until the mouse can not float out of the water surface after sinking to the water surface for 8s, and the time (min) from the beginning of swimming to exhaustion is recorded as the weight swimming time of the mouse. The results are shown in FIG. 5. The results show that: the swimming time under load was very significantly prolonged (P < 0.01) in the low dose group compared to the blank group, and prolonged but not significant in the other dose groups.
1.3 mouse forelimb grip Strength test
And (3) gavage compound multi-dimensional coenzyme Q10 effervescent tablets are continuously administrated for 30d, and are administrated for 60min at the last time, and forelimb grip strength is measured. Lifting the tail of the mouse, grabbing the grabbing plate by the front claw, slightly pulling the mouse backwards in parallel with the grabbing plate, automatically reading the maximum value by the instrument, measuring for 3 times, and taking out the average value as the fore limb grabbing value of the mouse. The results are shown in FIG. 6. The results show that: compared with the blank group, the grip strength of the forelimb of the mice in the low-dose group is remarkably increased (P is less than 0.05), and the grip strength of the forelimb of the mice in the medium-high dose group and the positive drug group is remarkably increased (P is less than 0.01).
1.4 mouse rod rotation experiment
The gavage compound multi-dimensional coenzyme Q10 effervescent tablet is continuously administrated for 30d, the last time of administration is 60min, and a fatigue bar rotating experiment with the rotating speed of 30r/min is carried out on a mouse. The adaptive training is carried out on the mouse 3 times before the formal experiment, the falling time of the mouse from the rotating rod is recorded in the formal experiment, the measurement is carried out for 3 times, and the average value is taken as the rotating rod time of the mouse. The results are shown in FIG. 7. The results show that: compared with a blank group, the rod rotating time of the mice in the low-dose group and the positive medicine group is remarkably increased (P is less than 0.01), and the rod rotating time of the mice in the medium-high dose group is increased but is not remarkable.
1.5 Pole climbing experiment of mice
The gavage compound multidimensional coenzyme Q10 effervescent tablet is continuously administrated for 30 days, the last administration is carried out for 60min, each test group of mice is placed on a clean unified organic glass rod (a rod climbing device is arranged in a water basin with the depth of 10cm and the water temperature of 15 ℃ during the test), the muscles of the mice are in a state of static tension during the rod climbing process, the time that the mice fall off the glass rod due to muscle fatigue is recorded, the time is parallelly measured for 3 times, and the average time measured by 3 times of tests is taken as the rod climbing time of the mice. The results are shown in FIG. 8. The results show that: compared with the blank group, the rod climbing time of the mice in the low-dose group is remarkably increased (P is less than 0.01), the rod climbing time of the mice in the medium-dose group is remarkably increased (P is less than 0.05), and the rod climbing time of the mice in the high-dose group and the positive drug group is increased but is not remarkable.
2.1 measurement of Biochemical indicators related to fatigue in mice
The gavage compound multi-dimensional coenzyme Q10 effervescent tablet is continuously administered for 30d, is administered for 60min at the last time, is subjected to non-load swimming for 60min, is rested for 60min, is immediately blood-taken, is killed after being anesthetized by pentobarbital injection, and is respectively taken from the liver and the gastrocnemius muscle tissue. The levels of superoxide dismutase (SOD), urea nitrogen (BUN) and blood lactic acid in serum and the liver glycogen content in liver were measured separately according to the kit instructions. The measurement result shows that: as shown in fig. 9, compared with the blank group, the serum MDA level of the mice in the low-dose group was very significantly reduced (P < 0.01), and the serum MDA levels of the mice in the medium-high dose group and the positive drug group were slightly reduced; as shown in FIG. 10, compared with the blank group, the levels of SOD in the serum of the mice in the low and medium dose groups were significantly increased (P < 0.01), and the levels of SOD in the serum of the mice in the high dose group and the positive drug group were slightly increased; as shown in fig. 11, the levels of LD in the serum of mice in the low, medium and high dose groups and the positive drug group were all significantly reduced (P < 0.01) compared to the blank group; as shown in fig. 12, the levels of BUN in the serum of mice in the low, medium, and high dose groups were significantly reduced compared to the blank group (P < 0.01); as shown in FIG. 13, liver glycogen levels were significantly increased in mice in the low, medium and high dose groups compared to the blank group (P < 0.01).
The method comprises the following steps of taking gastrocnemius tissues of a mouse after exercise, soaking the gastrocnemius tissues in formalin solution for fixation, dehydrating the gastrocnemius tissues by using ethanol, carrying out paraffin embedding, carrying out section cutting, carrying out hematoxylin-eosin (HE) staining, and observing the change of the tissue structure of the gastrocnemius. The results are shown in fig. 14, the gastrocnemius muscle of the blank group of mice has different degrees of injury, irregular arrangement of muscle fiber, disorder of striation and partial inward shift of muscle cell nucleus, and the gastrocnemius muscle injury of the administration group is obviously improved, the striation is clear, and the fiber arrangement is uniform.
Experiment 4 fluorescent quantitative PCR
The gastrocnemius tissue after mouse movement was taken, total RNA was extracted, reverse transcription was performed using mRNA as a template to obtain cDNA, and the contents of AMPK and PGC-1. alpha. were quantitatively analyzed by PCR, and the primer information is shown in Table 7. The results are shown in fig. 15, which shows that the AMPK and PGC-1 α gene expression levels in gastrocnemius tissues of fatigue mice are significantly increased in the high dose group compared to the blank group, and AMPK and PGC-1 α gene expression levels are also significantly increased in the other administration groups, but are not significant.
TABLE 7 primer information
Taking 30mg of gastrocnemius tissue of a mouse after movement, adding lysate, grinding by a tissue homogenizer, centrifuging, extracting total protein, carrying out protein quantification by a BCA method, separating proteins such as AMPK, p-AMPKP, PGC-1 alpha, Bcl-2, Bax, GAPDH and the like from the quantified protein by SDS-PAGE, taking out electrophoresis gel after electrophoresis is finished, transferring the electrophoresis gel to a membrane, successfully transferring the protein to a PVDF cellulose membrane, taking out the membrane, sealing the membrane, washing the membrane by TBST, incubating by using a specific primary antibody, washing the membrane by using TBST again, incubating by using a secondary antibody, and detecting the target protein by using a chemiluminescence kit. The results are shown in fig. 16 and 17, and the protein expressions of the AMPK/PGC-1 alpha pathway and the Bcl-2/Bax pathway are analyzed respectively, so that in the mitochondrial AMPK/PGC-1 alpha pathway, compared with the blank group, the protein expressions of AMPK, P-AMPKP and PGC-1 alpha in the high dose group are all significantly up-regulated (P is less than 0.05), and other administration groups also have an up-regulation trend; in the Bcl-2/Bax pathway, Bcl-2 is an important anti-apoptosis protein, compared with a blank group, the expression of the Bcl-2 protein in a high-dose group is obviously up-regulated (P is less than 0.05), and other administration groups are obviously up-regulated; compared with the blank group, Bax protein expression is remarkably reduced (P < 0.05) in the medium-dose group, and other administration groups also have a down-regulation trend.
And (4) conclusion:
the product is a compound effervescent solid preparation rich in vitamins, electrolytes, energy, myocardial protection and other effective components, and has effects of nourishing myocardium, supplementing energy and electrolytes, and relieving fatigue. Through various behavior experiments of mice, the combination of the determination of related biochemical indexes and the research of molecular mechanism, the compound multi-dimensional coenzyme Q10 effervescent tablet is proved to be capable of effectively enhancing exercise endurance and relieving exercise fatigue.
Claims (4)
1. A compound multivitamin coenzyme Q10 effervescent tablet is characterized in that: the composite material comprises the following components in percentage by mass:
the raw materials comprise, by weight, 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate.
2. The compound multidimensional Q10 effervescent tablet of claim 1, wherein: the filler is lactose; the adhesive is PVP K30; the sweetener is stevioside; the lubricant is PEG 6000.
3. The compound multidimensional coenzyme Q10 effervescent tablet of claim 1, wherein: the alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1-1.2: 1.
4. A preparation method of the compound multidimensional coenzyme Q10 effervescent tablet as claimed in claim 1, which is characterized in that: mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source according to the mass percentage, and half of a filler, an adhesive and a sweetening agent according to the mass percentage, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 in percentage by mass, grinding uniformly, adding an alkali source and half of filler, adhesive and sweetener in percentage by mass, sieving with a 20-mesh sieve, granulating, and drying to obtain alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210199609.0A CN114468196A (en) | 2022-03-02 | 2022-03-02 | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210199609.0A CN114468196A (en) | 2022-03-02 | 2022-03-02 | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114468196A true CN114468196A (en) | 2022-05-13 |
Family
ID=81484857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210199609.0A Pending CN114468196A (en) | 2022-03-02 | 2022-03-02 | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114468196A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116869109A (en) * | 2023-07-20 | 2023-10-13 | 广东润和生物科技有限公司 | Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200550B1 (en) * | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
JP2004242508A (en) * | 2003-02-10 | 2004-09-02 | Nisshin Pharma Inc | Food containing coenzyme q10 and water-soluble vitamin |
WO2005107737A1 (en) * | 2004-05-11 | 2005-11-17 | Kaneka Corporation | Antifatigue composition |
JP2007181441A (en) * | 2006-01-10 | 2007-07-19 | Nisshin Pharma Inc | Method for producing composition mixed with coenzyme q10 |
CN101019884A (en) * | 2006-02-16 | 2007-08-22 | 北京奇源益德药物研究所 | Compound coenzyme Q10 medicine prepn and its prepn process and application |
CN102389116A (en) * | 2011-11-23 | 2012-03-28 | 武汉工程大学 | Effervescent tablet for alleviating physical fatigue and preparation technology thereof |
CN104522646A (en) * | 2014-12-18 | 2015-04-22 | 无限极(中国)有限公司 | Composition with functions of enhancing immunity and relieving physical fatigue and application thereof |
CN107772446A (en) * | 2016-08-26 | 2018-03-09 | 华仁药业股份有限公司 | A kind of high-protein nutrient thing combination for Velocity-force class and preparation method thereof |
-
2022
- 2022-03-02 CN CN202210199609.0A patent/CN114468196A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200550B1 (en) * | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
JP2004242508A (en) * | 2003-02-10 | 2004-09-02 | Nisshin Pharma Inc | Food containing coenzyme q10 and water-soluble vitamin |
WO2005107737A1 (en) * | 2004-05-11 | 2005-11-17 | Kaneka Corporation | Antifatigue composition |
JP2007181441A (en) * | 2006-01-10 | 2007-07-19 | Nisshin Pharma Inc | Method for producing composition mixed with coenzyme q10 |
CN101019884A (en) * | 2006-02-16 | 2007-08-22 | 北京奇源益德药物研究所 | Compound coenzyme Q10 medicine prepn and its prepn process and application |
CN102389116A (en) * | 2011-11-23 | 2012-03-28 | 武汉工程大学 | Effervescent tablet for alleviating physical fatigue and preparation technology thereof |
CN104522646A (en) * | 2014-12-18 | 2015-04-22 | 无限极(中国)有限公司 | Composition with functions of enhancing immunity and relieving physical fatigue and application thereof |
CN107772446A (en) * | 2016-08-26 | 2018-03-09 | 华仁药业股份有限公司 | A kind of high-protein nutrient thing combination for Velocity-force class and preparation method thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116869109A (en) * | 2023-07-20 | 2023-10-13 | 广东润和生物科技有限公司 | Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guest et al. | International society of sports nutrition position stand: caffeine and exercise performance | |
Zhong et al. | Evaluation of anti-fatigue property of the extruded product of cereal grains mixed with Cordyceps militaris on mice | |
Williams | The use of nutritional ergogenic aids in sports: is it an ethical issue? | |
CN104187952B (en) | Ginseng-sealwort composite sports health beverage | |
AU2016262125B2 (en) | Amino acid supplementation | |
Grgic et al. | Caffeine supplementation for powerlifting competitions: An evidence-based approach | |
US20110123653A1 (en) | Compositions and methods for optimizing exercise recovery | |
CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
CN106820093A (en) | A kind of energy glue used suitable for marathon and running exercise and preparation method thereof | |
Dudgeon et al. | The effects of high and low-dose Cordyceps Militaris-containing mushroom blend supplementation after seven and twenty-eight days | |
US20240226077A1 (en) | Compositions and Methods for Increasing Athletic Performance | |
CN114468196A (en) | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof | |
CN106509540A (en) | Drink for enhancing immunity and improving athletic ability | |
CN113713049B (en) | Chinese medicinal compound preparation for assisting in resisting fatigue | |
Gonzalez et al. | Effect of multi-ingredient Preworkout supplementation on repeated Sprint performance in recreationally active men and women | |
CN101331950A (en) | Nutritional supplement for increasing sports break-out force | |
EP3154539B1 (en) | Method for decreasing skeletal muscle damage and/or oxidative stress in mammals | |
CN113229431A (en) | White-meat lucid ganoderma sports beverage and preparation method thereof | |
Rohmansyah et al. | The different effects of banana juice and sport drink on lactic acid among volleyball students in Surakarta | |
WO2022083685A1 (en) | Methods for improving exercise performance and endurance thereof | |
Putri et al. | Intermittent physical training decreases peak of blood glucose level after meals in rats | |
CN110064023B (en) | Anti-fatigue traditional Chinese medicine product and preparation method thereof | |
RU2822235C1 (en) | Method for metabolic correction of orlov trotters during drawing of traditional prizes | |
RU2783527C1 (en) | Method for energy immuno-metabolic correction, increase of resistance and stress resistance of sports horses in the prize period | |
RU2805360C1 (en) | Method for improving physical fitness of sporting horses, their adaptation to active muscular activity and stress in prize period |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |
|
RJ01 | Rejection of invention patent application after publication |